MG
TEVA icon

Mather Group’s Teva Pharmaceuticals TEVA Stock Holding History

Mather Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$305 Buy
+10
New +$322 ﹤0.01% 1829
2024
Q3 		– Sell
-339
Closed -$4.78K – 2165
2024
Q2 		$4.78K Buy
+339
New +$5.22K ﹤0.01% 1633

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mather Group's TEVA Position: Q1 2026 in Review

Mather Group opened a new position in Teva Pharmaceuticals (TEVA) in Q1 2026: 10 shares worth $305. The stake represents ﹤0.01% of the portfolio and ranks #1829 among its holdings. This is a return to the name: Mather Group previously reported a position in TEVA as recently as Q2 2024.

Mather Group first reported a position in TEVA in Q2 2024 and has held it in 2 quarters since. The position peaked at $4.78K in Q2 2024. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Mather Group held 10 shares of Teva Pharmaceuticals worth $305 as of Q1 2026.
  • Teva Pharmaceuticals was a new Mather Group position in Q1 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q1 2026, its #1829 holding.
  • Mather Group first reported a position in Teva Pharmaceuticals in Q2 2024 and has held it in 2 quarters since.
  • Mather Group's Teva Pharmaceuticals position peaked at $4.78K in Q2 2024.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Mather Group's 13F filing for Q1 2026, filed 13 Apr 2026.